Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Iradimed (IRMD) Invested Capital (2016 - 2026)

Iradimed has reported Invested Capital over the past 14 years, most recently at $98.5 million for Q1 2026.

  • Quarterly Invested Capital rose 9.39% to $98.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $98.5 million through Mar 2026, up 9.39% year-over-year, with the annual reading at $94.6 million for FY2025, 8.98% up from the prior year.
  • Invested Capital was $98.5 million for Q1 2026 at Iradimed, up from $94.6 million in the prior quarter.
  • Over five years, Invested Capital peaked at $98.5 million in Q1 2026 and troughed at $62.5 million in Q1 2022.
  • The 5-year median for Invested Capital is $76.1 million (2024), against an average of $79.6 million.
  • Year-over-year, Invested Capital fell 3.06% in 2023 and then increased 21.56% in 2024.
  • A 5-year view of Invested Capital shows it stood at $73.7 million in 2022, then fell by 3.06% to $71.4 million in 2023, then rose by 21.56% to $86.8 million in 2024, then grew by 8.98% to $94.6 million in 2025, then increased by 4.12% to $98.5 million in 2026.
  • Per Business Quant, the three most recent readings for IRMD's Invested Capital are $98.5 million (Q1 2026), $94.6 million (Q4 2025), and $98.4 million (Q3 2025).